Shield Therapeutics Announces Block Listing Application to London Stock Exchange

Shield Therapeutics ( (GB:STX) ) has issued an update.

Shield Therapeutics has applied for a block listing of 15,000,000 ordinary shares to the London Stock Exchange, which will be allocated to the company’s Retention and Performance Share Plan and admitted to trading on 23 December 2025. The application aligns with the company’s focus on iron deficiency treatments, notably ACCRUFeR®, positioning Shield Therapeutics as a leader in this $2.3 billion market, while enhancing operational flexibility and rewarding key personnel to support further growth.

The most recent analyst rating on (GB:STX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.

Spark’s Take on GB:STX Stock

According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.

The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.

To see Spark’s full report on GB:STX stock, click here.

More about Shield Therapeutics

Shield Therapeutics plc is a commercial-stage pharmaceutical company specializing in the development and delivery of ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative oral therapy addressing iron deficiency with or without anemia. The company operates globally through strategic partnerships and licensing agreements, with ACCRUFeR® marketed in the U.S., UK, EU, Canada, China, South Korea, Japan, and other regions.

Average Trading Volume: 3,193,916

Technical Sentiment Signal: Hold

Current Market Cap: £118.9M

For a thorough assessment of STX stock, go to TipRanks’ Stock Analysis page.